Stock Taper 
GENB
$17.14
▲ UP 0.12% (0.02)
KEY STATISTICS
Market Cap$2.20 B
52w High$22.67
52w Low$11.00
Dividend Yield—
Frequency—
P/E-32.96
Volume1.40M
Shares Out.128.19M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Mike Nally
ABOUT
SECTOR
Healthcare
WENT PUBLIC
February 27, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
312
PRICE TARGET
Target High$30.00
Target Low$22.00
Target Median$26.00
Target Consensus$26.00
UPCOMING EARNINGS
DateNov 5, 2026
DayThursday
Rev. Est.$7.75M
NOV
5
THU
PRICE
$17.14 ▲ UP 0.12% (+$0.02)About Generate Biomedicines, Inc.
https://generatebiomedicines.com ↗Generate Biomedicines uses machine learning to develop novel protein therapeutics, including monoclonal antibodies and CAR-T cells, through its Generate Platform for drug discovery in severe diseases like asthma.
INDUSTRY
Biotechnology
A PRODUCT GENERATE BIOMEDICINES, INC. IS KNOWN FOR
GB-0895
GB-0895 is a long-acting monoclonal antibody developed via AI, targeting TSLP to treat severe asthma, currently in Phase 3 trials and designed for six-month dosing.
ETFS HOLDING THIS STOCK
ETFS HOLDING
60
LISTED HERE
18
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
68.11%
HOLDERS
43
TOP 12 OF 43 · RANKED BY POSITION SIZE
Flagship Pioneering Inc.
Fmr LLC
Capital World Investors
Braidwell LP
Jpmorgan Chase & Co
Price T Rowe Associates Inc /Md/
Arch Venture Management, LLC
Harbourvest Partners LLC
Baker Bros. Advisors LP
Harvard Management Co Inc
Nvidia Corp
Siren, L.L.C.
RATINGS SNAPSHOT
Overall rating: C-
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
OVERWEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
